iOS app Android app


What If We Had No FDA?

Peter Schwartz | Posted 12.07.2015 | Politics
Peter Schwartz

The FDA has been given the power to force people to delay, whether for a day or forever, taking the medicines they believe will improve, or save, their lives. And the question we all should be asking is: By what right?

Training Immune System To Fight Cancer Comes Of Age

Reuters | Posted 07.07.2012 | Healthy Living

By Bill Berkrot NEW YORK, May 7 (Reuters) - More than 100 years after researchers first explored the potential to harness the body's ...

New Doubts About Prostate Cancer Vaccine

Reuters | Posted 05.30.2012 | Healthy Living

(Repeats story from earlier on Friday, March 30) * Paper criticizes study that led to approval * Manufacturer Dendreon d...

Medicare Will Cover $93,000 Prostate Cancer Drug

AP | By MATTHEW PERRONE | Posted 08.31.2011 | Healthy Living

WASHINGTON -- Medicare officials confirmed Thursday that the program will cover the $93,000 price tag for prostate cancer drug Provenge, an innovative...

Demanding Value in Health Care

Dr. Dennis Gottfried | Posted 07.26.2011 | Politics
Dr. Dennis Gottfried

Each time we decide a medical policy, a critical question that has been neglected up to now must be asked, "Is the care we are receiving worth the price we are paying?"

Sky High Drug Prices Impact Life-Or-Death Decisions

AP | MARILYNN MARCHIONE | Posted 11.17.2011 | Healthy Living

BOSTON — Cancer patients, brace yourselves. Many new drug treatments cost nearly $100,000 a year, sparking fresh debate about how much a few mon...

Dendreon Vaccine Approved By FDA Battles Advanced Prostate Cancer

AP | MATTHEW PERRONE | Posted 11.17.2011 | Healthy Living

WASHINGTON — A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval Thurs...

CANCER VACCINE PROVENGE: Dendreon Shares Rise On Drug Study Results

Yahoo! Finance | Posted 05.25.2011 | Home

Dendreon Inc. shares surged Wednesday as investors lauded the detailed study results for the drug developer's prostate cancer The stock doubled in...